Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
Timothy Iveson, et al.
2019年5月31日～6月4日に米国シカゴで開催された、米国臨床腫瘍学会年次集会（2019 Annual Meeting of the American Society of Clinical Oncology®）より、大腸癌・胃癌・膵癌などの消化器癌の注目演題のレポートをお届けします。臨床研究の第一線で活躍するドクターにより執筆、監修されたレポートを楽しみにしてください。
取材予定演題リスト
※本リストに掲載の演題は、発表前の限られた情報をもとに取材候補として選んだものです。
諸事情により、予告なく取材・掲載を取り止める場合がありますので、あらかじめご了承ください。
Colorectal Cancer
Oral Abstract #3501
Oral Abstract #3502
Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.
Qian Shi, et al.
Oral Abstract #3504
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.
Matthew T. Seymour, et al.
Oral Abstract #3507
Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ?3 baseline circulating tumor cells (bCTCs).
Javier Sastre, et al.
Oral Abstract #3508
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.
Chiara Cremolini, et al.
Poster Abstract #3512
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
Eric Xueyu Chen, et al.
Non-Colorectal Cancer
Plenary Abstract #LBA4
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
Hedy L. Kindler, et al.
Oral Abstract #LBA 4007
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Josep Tabernero, et al.
Oral Abstract #4000
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
Margaret A. Tempero, et al.
Oral Abstract #4001
ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).
Se Hoon Park, et al.
Oral Abstract #4002
A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial).
Namiki Izumi, et al.
Oral Abstract #4004
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Richard S. Finn, et al.
Oral Abstract #4006
Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.
Peter S Hall, et al.
Poster Abstract #4010
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
Manish A. Shah, et al.
Oral Abstract #4017
S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.
Rui-hua Xu, et al.
Poster Abstract #4019
Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).
Clarisse Eveno, et al.